Livzon Pharmaceutical Group EBIT

The latest EBIT for 1513.HK is $2.2B as of June 2026. That compares with $3B in the prior-year period — down 27.4% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Livzon Pharmaceutical Group's historical trend and sector peers before judging valuation or financial health.

Over the past year, 1513.HK's EBIT moved from $3B to $2.2B — a 27.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Livzon Pharmaceutical Group's operating scale or balance-sheet position.

Against its sector companies, 1513.HK currently prints $2.2B for EBIT, while the sector average sits near $2.6T. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Livzon Pharmaceutical Group's growth, margins, and balance sheet.

A EBIT figure of $2.2B for 1513.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 1513.HK's EBIT ($2.2B), review year-over-year change from $3B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.